Orchard Therapeutics to buy GSK’s rare disease gene therapy portfolio – Pharmaceutical Business Review
Pharmaceutical Business Review |
Orchard Therapeutics to buy GSK’s rare disease gene therapy portfolio
Pharmaceutical Business Review The acquisition of the portfolio, which includes both approved and investigational therapies like Strimvelis and a therapy for beta thalassaemia, is expected to consolidate Orchard’s position in gene therapy for rare diseases. Orchard also expects the … Gene Therapy and Antisense Drugs Developing New Market By 2025Pharmaceuticals News |
Science Friday |
More Options For Cancer Immunotherapy
Science Friday Tumors are masters of disguise. Unlike a virus or bacteria, a tumor’s cells are our cells. They produce molecules that can block immune system cells from recognizing them. Often, they mutate to shed other molecules that might flag the cell as unhealthy … |